Literature DB >> 15579454

Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Christian R Engwerda1, Manabu Ato, Simona Stäger, Clare E Alexander, Amanda C Stanley, Paul M Kaye.   

Abstract

Tumor necrosis factor (TNF) is critical for the control of visceral leishmaniasis caused by Leishmania donovani. However, the role of the related cytokine lymphotoxin (LT) alpha in this infection is unknown. Here we report that C57BL/6 mice deficient in TNF (B6.TNF(-/-)) or LT alpha (B6.LT alpha(-/-)) have increased susceptibility to hepatic L. donovani infection. Furthermore, the outcome of infection in bone marrow chimeric mice is dependent on donor hematopoietic cells, indicating that developmental defects in lymphoid organs were not responsible for increased susceptibility to L. donovani. Although both LT alpha and TNF regulated the migration of leukocytes into the sinusoidal area of the infected liver, their roles were distinct. LT alpha was essential for migration of leukocytes from periportal areas, an event consistent with LT alpha-dependent up-regulation of VCAM-1 on liver sinusoid lining cells, whereas TNF was essential for leukocyte recruitment to the liver. During visceral leishmaniasis, both cytokines were produced by radio-resistant cells and by CD4(+) T cells. LT alpha and TNF production by the former was required for granuloma assembly, while production of these cytokines by CD4(+) T cells was necessary to control parasite growth. The production of inducible nitric oxide synthase was also found to be deficient in TNF- and LT alpha-deficient infected mice. These results demonstrate that both LT alpha and TNF are required for control of L. donovani infection in noncompensatory ways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579454      PMCID: PMC1618729          DOI: 10.1016/s0002-9440(10)63262-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  Characterization of tumor necrosis factor-deficient mice.

Authors:  M W Marino; A Dunn; D Grail; M Inglese; Y Noguchi; E Richards; A Jungbluth; H Wada; M Moore; B Williamson; S Basu; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice.

Authors:  P A Koni; R Sacca; P Lawton; J L Browning; N H Ruddle; R A Flavell
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

3.  Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice.

Authors:  M B Alimzhanov; D V Kuprash; M H Kosco-Vilbois; A Luz; R L Turetskaya; A Tarakhovsky; K Rajewsky; S A Nedospasov; K Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  Destruction of follicular dendritic cells during chronic visceral leishmaniasis.

Authors:  S C Smelt; C R Engwerda; M McCrossen; P M Kaye
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

5.  CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice.

Authors:  C E Alexander; P M Kaye; C R Engwerda
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

6.  TNF alpha and LT alpha gene polymorphisms as additional markers of celiac disease susceptibility in a DQ2-positive population.

Authors:  José A Garrote; Eduardo Arranz; Juan J Tellería; Jesús Castro; Carmen Calvo; Alfredo Blanco-Quirós
Journal:  Immunogenetics       Date:  2002-10-03       Impact factor: 2.846

7.  Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Authors:  S R Ruuls; R M Hoek; V N Ngo; T McNeil; L A Lucian; M J Janatpour; H Körner; H Scheerens; E M Hessel; J G Cyster; L M McEvoy; J D Sedgwick
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

8.  Control of experimental Trypanosoma brucei infections occurs independently of lymphotoxin-alpha induction.

Authors:  S Magez; B Stijlemans; G Caljon; H-P Eugster; P De Baetselier
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

9.  A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Sara E J Cotterell; Tracey L Mynott; Asiya Tschannerl; Patricia M A Gorak-Stolinska; Paul M Kaye
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria.

Authors:  Christian R Engwerda; Tracey L Mynott; Sanjeet Sawhney; J Brian De Souza; Quentin D Bickle; Paul M Kaye
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

View more
  33 in total

Review 1.  Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.

Authors:  Thomas W Spahn; Hans-Pietro Eugster; Adriano Fontana; Wolfram Domschke; Torsten Kucharzik
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  IL-1β (-511T/C) gene polymorphism not IL-1β (+3953T/C) and LT-α (+252A/G) gene variants confers susceptibility to visceral leishmaniasis.

Authors:  Ali Moravej; Manoochehr Rasouli; Mehdi Kalani; Sadaf Asaei; Simin Kiany; Sohrab Najafipour; Amin Koohpayeh; Abbas Abdollahi
Journal:  Mol Biol Rep       Date:  2012-02-05       Impact factor: 2.316

Review 3.  LIGHT-related molecular network in the regulation of innate and adaptive immunity.

Authors:  Yanhui Xu; Koji Tamada; Lieping Chen
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Heme oxygenase-1 promotes the persistence of Leishmania chagasi infection.

Authors:  Nívea F Luz; Bruno B Andrade; Daniel F Feijó; Théo Araújo-Santos; Graziele Q Carvalho; Daniela Andrade; Daniel R Abánades; Enaldo V Melo; Angela M Silva; Cláudia I Brodskyn; Manoel Barral-Netto; Aldina Barral; Rodrigo P Soares; Roque P Almeida; Marcelo T Bozza; Valéria M Borges
Journal:  J Immunol       Date:  2012-03-28       Impact factor: 5.422

5.  Temporal expression of chemokines dictates the hepatic inflammatory infiltrate in a murine model of schistosomiasis.

Authors:  Melissa L Burke; Donald P McManus; Grant A Ramm; Mary Duke; Yuesheng Li; Malcolm K Jones; Geoffrey N Gobert
Journal:  PLoS Negl Trop Dis       Date:  2010-02-09

6.  Co-ordinated gene expression in the liver and spleen during Schistosoma japonicum infection regulates cell migration.

Authors:  Melissa L Burke; Donald P McManus; Grant A Ramm; Mary Duke; Yuesheng Li; Malcolm K Jones; Geoffrey N Gobert
Journal:  PLoS Negl Trop Dis       Date:  2010-05-18

Review 7.  Immunoregulation in human American leishmaniasis: balancing pathology and protection.

Authors:  K J Gollob; A G Viana; W O Dutra
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

8.  Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-γ production by spleen cells from human visceral leishmaniasis patients.

Authors:  Neetu Singh; Rajiv Kumar; Christian Engwerda; David Sacks; Susanne Nylen; Shyam Sundar
Journal:  Cytokine       Date:  2016-06-30       Impact factor: 3.861

9.  Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Authors:  Deepak Kumar Deep; Ruchi Singh; Arpita Kulshrestha; Saima Wajid; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

10.  Lymphotoxin-alpha and TNF have essential but independent roles in the evolution of the granulomatous response in experimental leprosy.

Authors:  Deanna A Hagge; Bernadette M Saunders; Gigi J Ebenezer; Nashone A Ray; Vilma T Marks; Warwick J Britton; James L Krahenbuhl; Linda B Adams
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.